Table 3.
Demographic characteristics and treatment antecedent of patients with- and without rifampicin resistance
| Characteristics | Patients with rifampicin resistance (N = 79) n (%) |
Patients without rifampicin resistance (N = 258) n (%) |
P value |
|---|---|---|---|
| Age (year) 0–14 | 0 (0) | 2 (0.7) | ----- |
| 15–24 | 14 (17.7) | 62 (24) | 0.24 |
| 25–34 | 26 (32.9) | 92 (35.6) | 0.65 |
| 35–44 | 19 (24) | 41 (15.9) | 0.09 |
| 45–54 | 9 (11.4) | 33 (12.8) | 0.74 |
| ≥ 55 | 7 (8.9) | 22 (8.5) | 0.92 |
| Female | 16 (20.2) | 63 (24.4) | 0.44 |
| HIV+ | 6 (7.6) | 36 (13.9) | 0.13 |
| Previously Treated | 69 (87.3) | 32 (12.4) | <0.01 |
| AFB Negative | 8 (10.1) | 6 (2.3) | <0.01 |
| 1+ or 2+ | 15 (18.9) | 21 (8.1) | <0.01 |
| 3+ | 55 (69.6) | 222 (86) | <0.01 |
AFB acid fast bacilli, 1+ smear AFB positive at 1+, 2+ smear AFB positive at 2+, 3+ smear AFB positive at 3+